Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;99(6):1487-1489.
doi: 10.1016/j.kint.2021.03.014. Epub 2021 Mar 26.

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Ilies Benotmane  1 , Gabriela Gautier-Vargas  2 , Noëlle Cognard  2 , Jérôme Olagne  2 , Françoise Heibel  2 , Laura Braun-Parvez  2 , Jonas Martzloff  2 , Peggy Perrin  2 , Bruno Moulin  3 , Samira Fafi-Kremer  4 , Sophie Caillard  3
Affiliations
Comment

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Ilies Benotmane et al. Kidney Int. 2021 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anti-spike IgG antibody titers measured at 28 days after vaccination in 215 seronegative kidney transplant recipients (median titer, <6.8 arbitrary units [AUs]/ml [interquartile range, <6.8−<6.8 AUs/ml]) and 26 seropositive kidney transplant recipients (median titer, 224 AUs/ml [interquartile range, 76−496 AUs/ml]). The dotted line indicates the cutoff for positivity (50 AUs/ml).
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Centers for Disease Control and Prevention. COVID-19 vaccination program operational guidance. Available at: https://www.cdc.gov/vaccines/covid-19/covid19-vaccination-guidance.html
    1. ECD. COVID-19 vaccination and prioritisation strategies in the EU/EEA. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccin...
    1. Jackson L.A., Anderson E.J., Rouphael N.G. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383:1920–1931. - PMC - PubMed
    1. Prendecki M., Clarke C., Brown J. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397:1178–1181. - PMC - PubMed